A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region

Brief description of study

Primary Objective:

To describe the clinical characteristics of participants with chronic rhinosinusitis with nasal polyps (CRSwNP) in terms of disease severity, Type 2 inflammation-related comorbidities (such as asthma and allergic rhinitis), other associated comorbidities, and treatments used in a real-world setting

Secondary Objectives:

Describe the progression in treatment outcomes at different visits (baseline, 3 months, 6 months, and 12 months).
To assess the healthcare resource utilization of participants with CRSwNP in countries of the Gulf region (number of visits, emergency room (ER), surgery, etc).

Detailed description of study

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Age: 18 Years
Gender: Male or Female

Inclusion Criteria:

Male or female participants.
Participants diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP) for at least one year prior to study start.
Participants diagnosed with CRSwNP according to criteria of American Academy of Otolaryngology-Head and Neck Surgery (i.e. the diagnosis is confirmed in medical records by clinical symptoms and objective evidence of nasal polyps by using anterior rhinoscopy and nasal endoscopy when available and/or computed tomography (CT) scan).
Participants should be at least 18 years old.
Participants must have signed an informed consent.

Exclusion Criteria:

Participants with chronic rhinosinusitis without nasal polyps (CRSsNP)
Pregnant/breastfeeding participants or participants planning for a pregnancy.
Participants participating in other interventional clinical trials involving any investigational drug.
Participants with granulomatous diseases such as vasculitis or sarcoidosis. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Updated on 14 Dec 2022 . Study ID: NCT05649813

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).